Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab Academic Article uri icon


MeSH Major

  • Antibodies, Monoclonal
  • Bortezomib
  • Iodine Radioisotopes
  • Lymphoma, Non-Hodgkin
  • Radioimmunotherapy


  • Abstract Radioimmunotherapy (RIT) is effective treatment for indolent non-Hodgkin lymphomas (NHLs), but response durations are usually limited, especially in aggressive NHL. We hypothesized that administration of bortezomib as a radiosensitizer with RIT would be tolerable and improve efficacy in NHL. This phase 1 dose-escalation study evaluated escalating doses of bortezomib combined with (131)I-tositumomab in patients with relapsed/refractory NHL. Twenty-five patients were treated. Treatment was well tolerated, with primarily hematologic toxicity. The maximum tolerated dose (MTD) was determined to be 0.9 mg/m(2) bortezomib, in combination with a standard dose of 75 cGy (131)I-tositumomab. Sixteen patients responded (64%), including 44% complete responses (CRs), with 82% CR in patients with follicular lymphoma (FL). At a median follow-up of 7 months, median progression-free survival was 7 months, and seven of 11 patients with FL remained in remission at a median of 22 months. In conclusion, bortezomib can be safely administered in combination with (131)I-tositumomab with promising response rates.

publication date

  • January 2015



  • Academic Article



  • eng

PubMed Central ID

  • PMC5176012

Digital Object Identifier (DOI)

  • 10.3109/10428194.2014.914195

PubMed ID

  • 24730538

Additional Document Info

start page

  • 342

end page

  • 6


  • 56


  • 2